LadRx Corporation
LadRx Corporation, a biopharmaceutical company, engages in research and development of chemotherapeutic drugs for solid tumors in the United States. The company offers linker activated drug releases (LADR) technology, a platform consists of an organic backbone that is attached to a chemotoxic agent that targets and delivers the chemotoxic agent to the tumor environment and release within the tumo… Read more
LadRx Corporation (LADX) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of March 2025: 0.259x
Based on the latest financial reports, LadRx Corporation (LADX) has a cash flow conversion efficiency ratio of 0.259x as of March 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-552.79K) by net assets ($-2.13 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
LadRx Corporation - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how LadRx Corporation's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
LadRx Corporation Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of LadRx Corporation ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Daios Plastics S.A.
AT:DAIOS
|
N/A |
|
Tatton Asset Management plc
LSE:TAM
|
0.130x |
|
Magnum Goldcorp Inc
PINK:MGIDF
|
0.168x |
|
Custodian REIT PLC
LSE:CREI
|
0.025x |
|
House of Jane Inc
PINK:HOJI
|
N/A |
|
EUROPEAN MEDICAL SOLUTIONS
BR:ALEMS
|
0.053x |
|
DENNY'S
BE:DE8
|
-0.120x |
|
WEWORK INDIA MANAGEMENT L
NSE:WEWORK
|
N/A |
Annual Cash Flow Conversion Efficiency for LadRx Corporation (2018–2024)
The table below shows the annual cash flow conversion efficiency of LadRx Corporation from 2018 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-1.42 Million | $-1.31 Million | 0.923x | -90.23% |
| 2023-12-31 | $107.35K | $1.01 Million | 9.444x | +105.03% |
| 2022-12-31 | $25.72K | $-4.83 Million | -187.887x | -7190.90% |
| 2021-12-31 | $4.78 Million | $-12.31 Million | -2.577x | -272.31% |
| 2020-12-31 | $8.87 Million | $-6.14 Million | -0.692x | -84.04% |
| 2019-12-31 | $15.20 Million | $-5.72 Million | -0.376x | +29.53% |
| 2018-12-31 | $20.36 Million | $-10.87 Million | -0.534x | -- |